Conatus Pharmaceuticals Inc. (CNAT)
(Delayed Data from NSDQ)
$0.90 USD
+0.05 (5.88%)
Updated May 3, 2019 03:59 PM ET
After-Market: $0.90 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.90 USD
+0.05 (5.88%)
Updated May 3, 2019 03:59 PM ET
After-Market: $0.90 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Intercept (ICPT) Gains 7.5% YTD on Progress in NASH Space
by Zacks Equity Research
Intercept (ICPT) stock gains as it becomes the forerunner in the NASH drug race.
NASH Scorecard Year to Date: The Winners and the Losers
by Ekta Bagri
NASH sees a highly rewarding market with candidates of blockbuster potential. Let us take a look at the hits and misses in this space so far this year.
Conatus Pharmaceuticals (CNAT) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Conatus (CNAT) delivered earnings and revenue surprises of 16.67% and -48.06%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Conatus Pharmaceuticals (CNAT) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
by Zacks Equity Research
Conatus (CNAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Phibro (PAHC) Suffers Dismal Segmental Sales, Margin Woes
by Zacks Equity Research
Per Phibro Animal (PAHC), weak demand in Animal Health business due to swine flu outbreak in China along with an unfavorable product mix in Mineral Nutrition is dampening.
Penumbra Enrolls First Patient for Study on Coronary Vessels
by Zacks Equity Research
Penumbra (PEN) gears up for the study of mechanical power aspiration as part of advancements in coronary treatment.
Top Ranked Momentum Stocks to Buy for September 10th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, September 10th
Conatus (CNAT) Upgraded to Strong Buy: Here's What You Should Know
by Zacks Equity Research
Conatus (CNAT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Conatus (CNAT) Beats on Q2 Earnings, Stops Emricasan Studies
by Zacks Equity Research
Conatus' (CNAT) earnings and revenues surpass estimates in the second quarter. However, the company stalls the development of its lead candidate emricasan.
Conatus Pharmaceuticals (CNAT) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Conatus (CNAT) delivered earnings and revenue surprises of 83.33% and 54.16%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Will Conatus Pharmaceuticals (CNAT) Report Negative Q2 Earnings? What You Should Know
by Zacks Equity Research
Conatus (CNAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biotech Stock Roundup: Vertex, AMAG Drugs Get FDA Nod, Conatus Study Fails & More
by Zacks Equity Research
Key highlights of the past week include regulatory approvals, collaborations and pipeline updates.
Conatus' Emricasan Lags Primary Goal in Liver Function Study
by Zacks Equity Research
Conatus' (CNAT) emricasan fails to meet the primary endpoint in the phase IIb ENCORE-LF study on decompensated NASH cirrhosis patients while the ENCORE-PH probe falls shy of the predefined objectives.
CymaBay Down on Dismal Interim Data From Mid-Stage NASH Study
by Zacks Equity Research
CymaBay (CBAY) plummets as a phase IIb study on lead candidate, seladelpar, fails to show meaningful reductions in liver fat.
Conatus (CNAT) Down 5.8% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Conatus (CNAT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Conatus Down More Than 60% in the Past 90 Days: Here's Why
by Zacks Equity Research
Conatus' (CNAT) lead candidate, emricasan, developed for treating patients with fibrosis or cirrhosis caused by NASH misses the primary endpoint in two mid-stage studies that hits the stock massively.
Conatus' (CNAT) Earnings, Revenues Miss Estimates in Q1
by Zacks Equity Research
Conatus, (CNAT) earnings and revenues lag estimates in the first-quarter of 2019. Emricasan remains in focus.
Conatus Pharmaceuticals (CNAT) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Conatus (CNAT) delivered earnings and revenue surprises of -16.67% and -15.00%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Conatus Pharmaceuticals (CNAT) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
by Zacks Equity Research
Conatus (CNAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Is Conatus (CNAT) Down 37.8% Since Last Earnings Report?
by Zacks Equity Research
Conatus (CNAT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
NASH Scorecard So Far This Year: A Look at the Hits & Misses
by Ekta Bagri
NASH is a highly lucrative market with blockbuster potential. Let us take a look at the winners and losers in this space so far in 2019.
Biotech Stock Roundup: BIIB & CNAT Crash on Study Failures, LXRX Gets CRL
by Zacks Equity Research
Key highlights of the past week are multiple study failures and other pipeline updates.
Conatus (CNAT) Declines on Failure of NASH Fibrosis Study
by Zacks Equity Research
Conatus' (CNAT) stock plunges as the phase IIb study on emricasan for the treatment of biopsy-confirmed NASH and liver fibrosis fails.
Conatus (CNAT) Focuses on Developing NASH Candidate Emricasan
by Zacks Equity Research
Conatus (CNAT) concentrates on the development of its lead candidate, emricasan, for treating patients with fibrosis or cirrhosis caused by NASH.
Implied Volatility Surging for Conatus (CNAT) Stock Options
by Zacks Equity Research
Conatus (CNAT) needs investors to pay close attention to the stock based on moves in the options market lately.